EE369 Cost-Effectiveness Analysis of Pembrolizumab as a Second-Line Therapy for Advanced Urothelial Carcinoma in the United States
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.635
https://www.valueinhealthjournal.com/article/S1098-3015(23)03765-8/fulltext
Section Title :
Section Order :
10127
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03765-8&doi=10.1016/j.jval.2023.09.635